Clinical trials: Neuroprotective Drugs
Aneurysm, Ruptured, Vasospasm, Intracranial
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
Previous work has demonstrated patients presenting with ruptured aneurysms that develop radiographic and clinical vasospasm have a higher permeability of the blood brain membrane.
- Conditions
- Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
- Trial name
- NCT04876638
- Testing
- Minocyclin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Southern California
Malondialdehyde, Melatonin
Oral Melatonin as Neuroprotectant in Preterm Infants
Preterm newborns survival rates are improved, but long-term disabilities are still common. Major destructive focal lesions became less common, the most predominant lesion at present is diffuse white matter (WM damage).
- Trial name
- NCT04235673
- Testing
- melatonin
- Where
- 4 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Francesca Garofoli
Brain Damage, Chronic
Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants
NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage.
- Trial name
- NEOBRAIN (NCT00544895)
- Where
- 12 sites in Austria, France and 5 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Cognition Disorders, HIV Infections
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs are used to treat this but are not entirely effective. Some other therapy could play a role.
- Trial name
- NCT00013585
- Testing
- Selegiline hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stroke, Acute Stroke
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Cerebrovascular Disorders
- Trial name
- NCT07167550
- Testing
- Dimephosphon®
- Where
- 6 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Tatchempharmpreparaty, JSC
Small Cell Lung Carcinoma
Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation).
- Trial name
- NCT01553916
- Testing
- Lithium Carbonate, Prophylactic cranial irradiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Stroke, Ischemic
Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention
Ischemic stroke is the leading cause of long-term disability in the United States. Endovascular intervention with mechanical thrombectomy has become the standard of care for acute large vessel occlusion (LVO) stroke since…
- Trial name
- NCT05032781
- Testing
- Intra-arterial cold saline, minocycline, and magnesium
- Where
- United States
- Sponsor
- Northwell Health
Ischemic Stroke
Efficacy and Safety of Mexidol® in Stroke Therapy
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo.
- Trial name
- MIR (NCT06437626)
- Testing
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Where
- 17 sites in Kazakhstan, Russia and 1 more
- Volunteers
- 304 people
- Sponsor
- Pharmasoft
Stroke
Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.
Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's very important to choose the right way of the management of the patient and an appropriate drugs.
- Trial name
- 3C (NCT01388738)
- Testing
- citicoline, L-Alpha glycerylphosphorylcholine, cerebrolysin
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Clinical Institute of the Brain, Russia
Acute Ischemic Stroke
Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness…
- Trial name
- Ischemic strok (NCT07260760)
- Volunteers
- 600 people
- Sponsor
- Qianfoshan Hospital
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Multiple Sclerosis, Long COVID
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making…
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese
- Trial name
- NCT06171152
- Testing
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Out-Of-Hospital Cardiac Arrest, Cardiac Arrest
Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest
Comatose patients resuscitated from Out-of-Hospital Cardiac Arrest (OHCA) often develop a complicated systemic inflammatory response and have a poor prognosis with neurological damage being the most common cause of death.
- Conditions
- Out-Of-Hospital Cardiac Arrest, Cardiac Arrest, Cardiac Arrest With Successful Resuscitation, Post Cardiac Arrest Syndrome
- Trial name
- STEROHCA (NCT04624776)
- Testing
- Methylprednisolone, Isotonic saline
- Where
- 2 sites in Denmark
- Volunteers
- 158 people
- Sponsor
- Christian Hassager
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Stroke, Acute, Ischemic
Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT
Background: Stroke is the third major cause of death and disability worldwide. It was shown that combining early reperfusion therapy (thrombolysis and/or thrombectomy) with stroke unit care and immediate rehabilitation have…
- Trial name
- NCT05124353
- Testing
- Cerebrolysin
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Acute Ischemic Stroke, Large Vessel Occlusion
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS.
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
- Trial name
- GALLOP2 (NCT06788626)
- Testing
- Semaglutide 0.5 mg, Standard medical treatment
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Wei Hu
Acute Ischemic Stroke
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is…
- Trial name
- MACSI (NCT00893867)
- Testing
- DP-b99
- Where
- 154 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- D-Pharm Ltd.
Addiction;Drug(S);LSD, Neuroprotective
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions.
- Trial name
- NCT06550167
- Testing
- Nano-PSO, Pomegranate seed oil (omega-5)
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Distribuidora Biolife SA de CV
Acute Ischemic Stroke
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
- Trial name
- NCT06403267
- Testing
- NoNO-42
- Where
- 9 sites in Canada
- Volunteers
- 600 people
- Sponsor
- NoNO Inc.